Ebelactone A Microbial
| Catalog number: | B2014233 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | 338.48 g/mol |
| Supplied as: | Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | Ebelactone A microbial |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Ostrowska H, Kalinowska J, Chabielska E, Stankiewicz A, Kruszewski K, Buczko W. Ebelactone B, an inhibitor of extracellular cathepsin A-type enzyme, suppresses platelet aggregation ex vivo in renovascular hypertensive rats J Cardiovasc Pharmacol. 2005 Apr;45(4):348-53.
- Wyatt MA, Ahilan Y, Argyropoulos P, Boddy CN, Magarvey NA, Harrison PH. Biosynthesis of ebelactone A: isotopic tracer, advanced precursor and genetic studies reveal a thioesterase-independent cyclization to give a polyketide _-lactone J Antibiot (Tokyo). 2013 Jul;66(7):421-30.
- Umezawa H, Aoyagi T, Uotani K, Hamada M, Takeuchi T, Takahashi S. Ebelactone, an inhibitor of esterase, produced by actinomycetes J Antibiot (Tokyo). 1980 Dec;33(12):1594-6.
- Ostrowska H, Dabrowska M, Osada J, Mantur M. Effects of ebelactone B on cathepsin A activity in intact platelets and on platelet activation Rocz Akad Med Bialymst. 2003;48:150-3.
- Uotani K, Naganawa H, Aoyagi T, Umezawa H. Biosynthetic studies of ebelactone A and B by 13C NMR spectrometry J Antibiot (Tokyo). 1982 Dec;35(12):1670-4.
- Nonaka Y, Ohtaki H, Ohtsuka E, Kocha T, Fukuda T, Takeuchi T, Aoyagi T. Effects of ebelactone B, a lipase inhibitor, on intestinal fat absorption in the rat J Enzyme Inhib. 1996;10(1):57-63.
- Uotani K, Naganawa H, Kondo S, Aoyagi T, Umezawa H. Structural studies on ebelactone A and B, esterase inhibitors produced by actinomycetes J Antibiot (Tokyo). 1982 Nov;35(11):1495-9.
- Majima M, Ikeda Y, Kuribayashi Y, Mizogami S, Katori M, Aoyagi T. Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats Eur J Pharmacol. 1995 Sep 15;284(1-2):1-11.
- Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats Br J Pharmacol. 1999 Feb;126(3):613-20.
